On October 28, 2024, Research Team from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"), HKEX stock code: 01541.HK), announced that preclinical study data of IMM2520 were published in the journal Heliyon under the title "IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy".

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, Dr. Tian Wenzhi, the company's founder and chairman, will participate The 26th BIO CEO & Investor Conference which will be held in New York, USA from February 26th to 27th, to deliver a speech at 1:45pm on February 26, 2024 EST to fully demonstrate ImmuneOnco's innovative product pipeline and clinical research and development progress.

On February 16, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the research team of ImmuneOnco completed the preclinical study of IMM2902. The results were published in "Drug Resistance Updates" under the title "Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy".

On October 4, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that total 3 innovative clinical Phase II data of Timdarpacept (IMM01), the first SIRPαFc fusion protein targeting human CD47 in China, will be reported at the 2023 American Society of Hematology (ASH) Annual Meeting. Two phase II clinical data summary, for first-line MDS therapy and for cHL indications after PD1 antibody treatment failure will be presented orally, research results of first-line for CMML indication were presented in form of poster.

On September 26, 2023,the R&D team of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) reported the preclinical research results of IMM40H under the tittle of ‘The Novel High-Affinity Humanized Antibody IMM40H Targets CD70, Eliminates Tumors Via Fc-mediated Effector Functions, and Interrupts CD70/CD27 Signaling’in the top journal Frontiers in Oncology’

Recently, the R&D team of ImmuneOnco reports the preclinical research results of IMM47 under the tittle of IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy " in the journal "Antibody Therapeutics".

On September 11, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that IMM27M， an independently developed ADCC-enhanced CTLA-4 antibody, completed the phase I dose escalation patient enrollment and determined the recommended phase II dose.

On March 21, 2023, ImmuneOnco announced that the company will present the preclinical research data of IMM47 (CD24 antibody), IMM40H (CD70 antibody), IMM2520 (CD47×PD-L1), and IMM2902 (CD47×Her2) in the form of posters at the AACR 2023 Annual Meeting .

On March 28, 2022, ImmuneOnco announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cancer Research (AACR) hold in New Orleans from April 8 to 13.